BR112022015002A2 - Ligante de il-7r-alfa/gama/c, composto, composição farmacêutica, método para tratar uma doença em um paciente e ácido nucleico - Google Patents
Ligante de il-7r-alfa/gama/c, composto, composição farmacêutica, método para tratar uma doença em um paciente e ácido nucleicoInfo
- Publication number
- BR112022015002A2 BR112022015002A2 BR112022015002A BR112022015002A BR112022015002A2 BR 112022015002 A2 BR112022015002 A2 BR 112022015002A2 BR 112022015002 A BR112022015002 A BR 112022015002A BR 112022015002 A BR112022015002 A BR 112022015002A BR 112022015002 A2 BR112022015002 A2 BR 112022015002A2
- Authority
- BR
- Brazil
- Prior art keywords
- gamma
- alpha
- ligand
- disease
- patient
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5418—IL-7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062969432P | 2020-02-03 | 2020-02-03 | |
| US202063041158P | 2020-06-19 | 2020-06-19 | |
| PCT/US2021/016361 WO2021158623A1 (en) | 2020-02-03 | 2021-02-03 | IL-7Rαγc BINDING COMPOUNDS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022015002A2 true BR112022015002A2 (pt) | 2022-12-06 |
Family
ID=77200524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022015002A BR112022015002A2 (pt) | 2020-02-03 | 2021-02-03 | Ligante de il-7r-alfa/gama/c, composto, composição farmacêutica, método para tratar uma doença em um paciente e ácido nucleico |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11746139B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4100427A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023514128A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220139918A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115315435A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2021217353A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022015002A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3166816A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL295304A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022009390A (cg-RX-API-DMAC7.html) |
| TW (2) | TWI812918B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021158623A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210055694A (ko) | 2018-08-06 | 2021-05-17 | 메디카인 인코포레이티드 | Il-2 수용체 결합 화합물 |
| CA3160466A1 (en) | 2019-11-05 | 2021-05-14 | Medikine, Inc. | Dual il-2r and il-7r binding compounds |
| MX2022005411A (es) | 2019-11-05 | 2022-08-10 | Medikine Inc | COMPUESTOS DE UNIÓN A IL-2RßYC. |
| US11746139B2 (en) * | 2020-02-03 | 2023-09-05 | Medikine, Inc. | IL-7Rαγc binding compounds |
| AU2021217959A1 (en) * | 2020-02-03 | 2022-08-18 | Medikine, Inc. | IL-7Rα binding compounds |
| EP4240394A4 (en) * | 2020-11-04 | 2024-10-23 | Medikine, Inc. | IL-2R BETA-GAMMA C-BINDING COMPOUNDS AND USES THEREOF |
| US20250082777A1 (en) | 2022-01-10 | 2025-03-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| US11999771B2 (en) | 2022-04-07 | 2024-06-04 | Medikine, Inc. | IL-7Rαγc ligand immunoglobulin fusion proteins |
| US20240101959A1 (en) | 2022-09-06 | 2024-03-28 | Medikine, Inc. | Use of il-2r-beta-gamma agonist peptides in cell manufacturing |
| US20240100159A1 (en) | 2022-09-06 | 2024-03-28 | Medikine, Inc. | Use of il-7r-alpha-gamma agonist peptides in cell manufacturing |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635597A (en) | 1994-05-27 | 1997-06-03 | Affymax Technologies, N.V. | Peptides that bind IL-2 receptors |
| EP1454138B1 (en) | 2001-12-04 | 2012-01-18 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
| US20050054054A1 (en) * | 2002-11-12 | 2005-03-10 | Foss Francine M. | Interleukin-7 molecules with altered biological properties |
| KR101163424B1 (ko) | 2003-12-30 | 2012-07-13 | 메르크 파텐트 게엠베하 | Il-7 융합 단백질 |
| CN101072793B (zh) | 2004-12-09 | 2012-06-20 | 默克专利有限公司 | 具有降低的免疫原性的il-7变体 |
| EP1828231A2 (en) | 2004-12-22 | 2007-09-05 | Novartis Vaccines and Diagnostics, Inc. | Group b streptococcus |
| US20120210458A9 (en) | 2009-02-27 | 2012-08-16 | Yongwei Cao | Isolated Novel Nucleic Acid and Protein Molecules from Corn and Methods of Using Thereof |
| ES2866674T3 (es) | 2010-11-12 | 2021-10-19 | Nektar Therapeutics | Conjugados de una fracción de IL-2 y un polímero |
| EP2649094B1 (en) * | 2010-12-10 | 2016-04-27 | University of Central Florida Research Foundation, Inc. | Methods and compositions comprising il-7 receptor ligands |
| CA2824515C (en) | 2011-01-18 | 2022-09-13 | Bioniz, Llc | Compositions and methods for modulating gamma-c-cytokine activity |
| JP6592505B2 (ja) | 2014-04-24 | 2019-10-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト |
| KR102493543B1 (ko) | 2014-07-21 | 2023-01-30 | 데리니아, 인크. | 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자 |
| JP6640834B2 (ja) | 2014-08-11 | 2020-02-05 | デリニア, インコーポレイテッド | 自己免疫疾患の処置のために調節性t細胞を選択的に活性化させる改変il−2変異体 |
| PT3328894T (pt) * | 2015-08-06 | 2019-02-13 | Agency Science Tech & Res | Anticorpos de cadeia comum gama/il2rbeta |
| KR102908806B1 (ko) | 2015-10-22 | 2026-01-07 | 주노 테라퓨틱스 게엠베하 | 세포의 배양 방법 및 이를 위한 키트와 장치 |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| US11053293B2 (en) | 2016-02-05 | 2021-07-06 | Washington University | Compositions and methods for targeted cytokine delivery |
| EP3538548A4 (en) | 2016-11-08 | 2020-08-19 | Delinia, Inc. | IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
| CN110392695B (zh) * | 2016-12-09 | 2021-02-02 | Ose免疫疗法 | 针对cd127的抗体和多肽 |
| CN110177564A (zh) | 2016-12-13 | 2019-08-27 | 德里尼亚公司 | 多价的调节t细胞调节剂 |
| KR20210055694A (ko) | 2018-08-06 | 2021-05-17 | 메디카인 인코포레이티드 | Il-2 수용체 결합 화합물 |
| WO2020247388A2 (en) | 2019-06-03 | 2020-12-10 | Medikine, Inc. | Il-2alpha receptor subunit binding compounds |
| MX2022005411A (es) | 2019-11-05 | 2022-08-10 | Medikine Inc | COMPUESTOS DE UNIÓN A IL-2RßYC. |
| US20220119492A1 (en) | 2019-11-05 | 2022-04-21 | Medikine, Inc. | Il-2r-beta-gamma binding compounds and uses thereof |
| CA3160466A1 (en) | 2019-11-05 | 2021-05-14 | Medikine, Inc. | Dual il-2r and il-7r binding compounds |
| TW202136287A (zh) | 2019-12-17 | 2021-10-01 | 法商Ose免疫治療公司 | 包含il-7變體之雙官能分子 |
| AU2021217959A1 (en) | 2020-02-03 | 2022-08-18 | Medikine, Inc. | IL-7Rα binding compounds |
| US11746139B2 (en) | 2020-02-03 | 2023-09-05 | Medikine, Inc. | IL-7Rαγc binding compounds |
| EP4240394A4 (en) | 2020-11-04 | 2024-10-23 | Medikine, Inc. | IL-2R BETA-GAMMA C-BINDING COMPOUNDS AND USES THEREOF |
| US11999771B2 (en) | 2022-04-07 | 2024-06-04 | Medikine, Inc. | IL-7Rαγc ligand immunoglobulin fusion proteins |
-
2021
- 2021-02-03 US US17/166,462 patent/US11746139B2/en active Active
- 2021-02-03 CA CA3166816A patent/CA3166816A1/en active Pending
- 2021-02-03 EP EP21750982.7A patent/EP4100427A4/en not_active Withdrawn
- 2021-02-03 TW TW110104084A patent/TWI812918B/zh not_active IP Right Cessation
- 2021-02-03 BR BR112022015002A patent/BR112022015002A2/pt not_active IP Right Cessation
- 2021-02-03 JP JP2022547164A patent/JP2023514128A/ja active Pending
- 2021-02-03 WO PCT/US2021/016361 patent/WO2021158623A1/en not_active Ceased
- 2021-02-03 MX MX2022009390A patent/MX2022009390A/es unknown
- 2021-02-03 AU AU2021217353A patent/AU2021217353A1/en not_active Abandoned
- 2021-02-03 TW TW112126553A patent/TW202342505A/zh unknown
- 2021-02-03 CN CN202180022881.5A patent/CN115315435A/zh not_active Withdrawn
- 2021-02-03 IL IL295304A patent/IL295304A/en unknown
- 2021-02-03 KR KR1020227030327A patent/KR20220139918A/ko not_active Withdrawn
-
2023
- 2023-07-11 US US18/350,543 patent/US11965015B2/en active Active
-
2024
- 2024-03-21 AU AU2024201860A patent/AU2024201860A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220139918A (ko) | 2022-10-17 |
| MX2022009390A (es) | 2022-11-16 |
| US20230357358A1 (en) | 2023-11-09 |
| TW202342505A (zh) | 2023-11-01 |
| AU2021217353A1 (en) | 2022-08-25 |
| CN115315435A (zh) | 2022-11-08 |
| CA3166816A1 (en) | 2021-08-12 |
| IL295304A (en) | 2022-10-01 |
| JP2023514128A (ja) | 2023-04-05 |
| WO2021158623A1 (en) | 2021-08-12 |
| EP4100427A4 (en) | 2024-01-17 |
| US11746139B2 (en) | 2023-09-05 |
| AU2024201860A1 (en) | 2024-05-16 |
| US11965015B2 (en) | 2024-04-23 |
| TWI812918B (zh) | 2023-08-21 |
| TW202144390A (zh) | 2021-12-01 |
| US20210253670A1 (en) | 2021-08-19 |
| EP4100427A1 (en) | 2022-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022008744A2 (pt) | Ligante de il-2rss, ligante de il-2r¿c, composto de ligação a il-2r¿¿c, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método de uma terapia celular, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico | |
| BR112022008750A2 (pt) | Composto de ligação de receptor duplo, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico | |
| CL2024003895A1 (es) | Proteínas que se unen a nkg2d, flt3 y cd16; composición farmacéutica; y su uso. | |
| BR112021021224A2 (pt) | Anticorpos ou fragmentos de anticorpos, composição farmacêutica, kit, ácido nucleico ou conjunto de ácidos nucleicos, célula hospedeira recombinante e método para o tratamento ou a prevenção de uma doença em um paciente em necessidade do mesmo | |
| JOP20200315B1 (ar) | مركبات بورينون واستخدامها في معالجة السرطان | |
| BR112021024674A2 (pt) | Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo | |
| AR122018A1 (es) | Proteínas que se unen a nkg2d, cd16 y clec12a | |
| MX2020007060A (es) | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas. | |
| BR112022024483A2 (pt) | Métodos para tratar mieloma múltiplo | |
| BR112022001324A2 (pt) | Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo | |
| BRPI0912411B8 (pt) | uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune | |
| BR112016002496A2 (pt) | composto de fórmula i, composição farmacêutica, método para inibição de kdm1a, método para tratamento de uma doença mediada por globina, método para atingir um efeito em um paciente, e, método para inibir pelo menos uma função de kdm1a | |
| EA200700501A1 (ru) | Композиция (варианты) и способ для лечения гиперпролиферативных процессов, способ лечения рака (варианты) и способ получения твёрдой дисперсии вещества | |
| EA201500373A1 (ru) | Маситиниб или его соль для лечения рака, фармацевтическая композиция, лекарственное средство и набор | |
| ECSP066833A (es) | Compuestos heterocíclicos anticitocina | |
| BR112012024590A2 (pt) | métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos | |
| CO2024003967A2 (es) | Proteínas que se unen a nkg2d, cd16 y baff-r | |
| MX2022009390A (es) | Compuestos de unión a il-7r¿¿c. | |
| BR112020024412A8 (pt) | Anticorpos, composição farmacêutica, kit, ácido nucleico, célula hospedeira, métodos de tratamento ou prevenção de câncer, de redução da atividade, de aumento da atividade e de aumento da ativação | |
| BR112023002116A2 (pt) | Proteínas que se ligam a nkg2d, cd16 e egfr | |
| MX2020002429A (es) | Compuestos para reducir la viscosidad de las formulaciones biologicas. | |
| JOP20200242A1 (ar) | مركبات البلاديينوليد واستخداماتها | |
| BR112017026535A2 (pt) | composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto | |
| BR112023018237A2 (pt) | Fenalquilaminas e métodos para fabricação e uso das mesmas | |
| WO2023097194A3 (en) | Bicyclic therapeutic compounds and methods of use in the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2865 DE 02-12-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |